.



Figure 1 Participant flow

Variables	Total	1-pill group	2-pill group	*p*
N	146	71	75	
Age (years)	56.0 ± 15.3 (138)	55.1 ± 15.8 (68)	56.9 ± 14.8 (70)	0.50
Female (%)	34.5 (50/145)	35.2 (25/71)	33.8 (25/74)	1.00
Duration of Hypertension (years)	8.8 (3.5 - 15.0) (132)	8.0 (3.4 - 16.1) (64)	9.5 (3.8 - 15.0) (68)	0.81
Baseline SBP (mmHg)	147.8 ± 9.6 (146)	148.3 ± 9.2 (71)	147.3 ± 10.0 (75)	0.51
Baseline DBP (mmHg)	92.0 ± 10.2 (146)	91.8 ± 10.6 (71)	92.2 ± 9.8 (75)	0.85
Body mass index (kg/m^2)	27.3 ± 4.0 (146)	27.3 ± 4.2 (71)	27.3 ± 3.7 (75)	0.99
Current smoking (%)	15.2 (22/145)	11.3 (8/71)	18.9 (14/74)	0.29
Exercise >= x3/week (%)	29.9 (43/144)	34.3 (24/70)	25.7 (19/74)	0.34
Alcohol intake >= x3/week (%)	20.7 (30/145)	14.1 (10/71)	27.0 (20/74)	0.09
Any adverse events (%)	40.4 (59/146)	43.7 (31/71)	37.3 (28/75)	0.54
Drug-related adverse reaction (%)	16.4 (24/146)	23.9 (17/71)	9.3 (7/75)	< 0.05
Early termination (%)	12.3 (18/146)	11.3 (8/71)	13.3 (10/75)	0.90

Table 1 Baseline clinical characteristics

Outcomes	1-pill group	2-pill group	*p*
PDT (%)	95.1 (87.9 - 100.0) (65)	93.1 (73.9 - 97.9) (66)	< 0.05
PDTc (%)	91.7 (79.8 - 96.5) (65)	91.3 (70.7 - 96.4) (65)	< 0.05

Table 2 Primary outcomes

Outcomes	1-pill group	2-pill group	*p*
PDT ≥ 80% (%)	86.2 (56/65)	69.7 (46/66)	< 0.05
PDTc ≥ 80% (%)	73.8 (48/65)	61.5 (40/65)	0.19
Clinic SBP change (mmHg)	-19.3 ± 15.3 (63)	-17.2 ± 15.1 (64)	0.44

Table 3 Secondary outcomes

Serious adverse events: Two subjects, both allocated to the single-pill group, underwent serious adverse events occurred during the study. One subject underwent knee surgery due to degenerative joint disease and the other was admitted and operated due to acute appendicitis. Both were discharged uneventfully and none of these events were considered to be related directly to the clinical trial

Other adverse events: Drug-related adverse reaction was reported in 24 patients and significantly more prevalent in the single-pill group (Table 1). Among the single pill group 15 of 17 patients complained dizziness and/or fatigue and the other two experienced palpitation and leg edema respectively. Among the two-pill group, 5 of 7 patients complained dizziness and/or weakness and other patients reported palpitation and diplopia. Most of the patients

graded it as 'mild' in severity except for two subjects who graded it as 'moderate'. Four patients terminated the follow-up due to drug-related adverse effect (2/8 in the single-pill group and 2/10 in the two-pill group, not significantly different).